Barclays Keeps Equal-Weight Rating on Privia Health Group (PRVA)
Barclays Coverage: Barclays has maintained an Equal-Weight recommendation for Privia Health Group (NasdaqGS:PRVA) as of October 9, 2025, with an average one-year price target of $31.19/share, indicating a potential upside of 28.89% from its current price of $24.20/share.
Fund Sentiment and Ownership: There are 570 funds reporting positions in Privia Health Group, with a 7.55% increase in ownership over the last quarter. Notable shareholders include Durable Capital Partners and IJR - iShares Core S&P Small-Cap ETF, with varying changes in their portfolio allocations.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on PRVA
About PRVA
About the author
BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.